Modulating the dynamics of protein kinases expands the inhibitory mechanisms for small molecules. NMR measurements of the MAP kinase, ERK2, have shown that activation by dualphosphorylation induces global motions involving exchange between two states, "L'' and "R".
SIGNIFICANCE STATEMENT
Protein kinases in the RAF/MKK/ERK signaling pathway are dysregulated in cancer and are important targets for inhibitor development. Catalytic activation of the MAP kinase, ERK2, induces global motions involving exchange between two conformational states. Using nuclear magnetic resonance (NMR) and hydrogen-exchange mass spectrometry, we show that inhibitors exploit these motions to trap ERK2 in distinct states. Our findings reveal motions of the activation loop coupled to the active site. Inhibitor binding can control these activation loop dynamics to alter its rate of dephosphorylation by MAP kinase phosphatase.
\body INTRODUCTION
Extracellular-regulated kinases (ERK1/2) are key enzymes in the MAP kinase pathway, downstream of A/B/C-RAF and MAP kinase kinase-1/2 (MKK1/2, aka MEK1/2). ERKs are tightly regulated, with full activation following dual phosphorylation by MKK1/2, and inactivation following dephosphorylation by MAP kinase phosphatases (e.g. MKP3/DUSP6). The prevalence of oncogenic BRAF mutations in melanoma and other cancers has led to the development of inhibitors targeting BRAF-V600E/K and MKK1/2 (1). While these inhibitors have achieved dramatic success in clinic for metastatic melanoma, many patients develop resistance, often due to reactivation of ERK signaling (1) . Because of this, ERKs are potential targets for therapeutics, with high-affinity inhibitors in early-stage clinical trials (2, 3) . Therefore, understanding regulatory mechanisms for ERKs and how they impact inhibitor binding is a timely and important goal.
Crystal structures of ERK2 in its inactive, unphosphorylated (0P) and active, phosphorylated (2P) forms show a major conformational rearrangement of the activation loop following phosphorylation at regulatory sites, T183 and Y185 (numbered as in rat ERK2, Fig. S1 ) (4, 5) .
Other conformational changes include a small rotation and closure between N-and C-terminal domains and exposure of a docking motif binding site below the activation loop (4) (5) (6) . In other kinases, phosphorylation and remodeling of the activation loop cause significant structural changes that position active site residues for catalysis (7) . Curiously, the positions of these catalytic residues differ little between 0P-and 2P-ERK2 and resemble those seen in active conformations of most protein kinases (8) . This suggests that additional factors are needed to explain why 0P-ERK2 is inactive until phosphorylated.
Solution measurements of ERK2 have revealed changes in protein dynamics following kinase activation. Studies using hydrogen-deuterium exchange mass spectrometry (HX-MS) showed that phosphorylation of ERK2 alters rates of hydrogen exchange in localized regions, which can be ascribed to changes in conformational mobility (9) . NMR ( C]Ile, Leu, and Val revealed global motions throughout the kinase core upon activation by phosphorylation (10, 11) . Global exchange could be modeled by an equilibrium between two conformational states, named "L" (locked) and "R" (released), interconverting on a millisecond timescale. Thus, allosteric regulation of ERK2 involves constraint of the unphosphorylated kinase in the L state, and formation of the R state upon phosphorylation and associated activation. The conformational changes accompanying L⇌R interconversion and how they compare to those of other kinases have not been elucidated.
Clues to defining R and L have been provided by small molecules with differential binding properties to 0P-and 2P-ERK2. For example, the pyrimidylpyrrole inhibitor, Vertex-11e (12), has 7-fold higher affinity for 2P-ERK2 over 0P-ERK2 (Table S1 ) and shifts the L⇌R equilibrium in 2P-ERK2 completely to the R state (13) . In a second example, the non-hydrolyzable nucleotide, AMP-PNP, leads to greater protection of the catalytic site from solvent D 2 O in 2P-ERK2 than in 0P-ERK2, as measured by HX-MS (14,15) Such findings suggest that the L⇌R equilibrium in 2P-ERK2 allows conformational selection, a property characteristic of Type II kinase inhibitors (16) . Type II inhibitors recognize the conserved DFG motif, which coordinates Mg 2+ -ATP. They selectively bind to an inactive "DFG-out" conformation, which is in exchange with the active "DFG-in" conformation. Such conformation selectivity may shift exchanging populations of a kinase into one major state. However, current X-ray structures of ERK2 show no evidence for a DFG-in/DFG-out switch (4, 5) . The ways in which conformation-selective inhibitors affect 2P-ERK2 structure and dynamics, their relationship to DFG-in/DFG-out states, and their impact on regulation, are currently unresolved.
The goal of this study is to characterize the L⇌R equilibrium in 2P-ERK2 and its impact on kinase regulation. Solution (NMR, HX-MS) and structural (X-ray) measurements are integrated to examine interactions between ERK2 and inhibitors (Vertex-11e, GDC-0994, and SCH772984/SCH-CPD336; Fig. S2 ) or AMP-PNP. We demonstrate that both Vertex-11e and SCH772984 show properties of conformational selection when bound to 2P-ERK2, shifting the L⇌R equilibrium in opposite directions to R and L, respectively, while GDC-0994 and AMP-PNP binding allow equilibrium exchange, in a manner favoring R. X-ray structures of ERK2 complexed with nucleotide reveal that the L R transition is associated with a shift from nonproductive to productive nucleotide binding mode. We used this method to determine R:L population ratios for ERK2 complexed with three nanomolar affinity inhibitors, Vertex-11e, SCH772984, and GDC-0994 (Fig. S2 , Table S1 ) (12, 17, 18) . When complexed with Vertex-11e, the [ (Fig. 1B) as described (13) . In contrast, SCH772984 complexed with 2P-ERK2 resulted in a complete shift to the L state (Fig. 1C) . Binding of GDC-0994 as well as the ATP analogue, AMP-PNP, to 2P-ERK2 resulted in R:L ratios similar to apoenzyme (Fig. 1D,E) .
None of the ligands altered the dominant L state in 0P-ERK2. The results reveal that various ligands exploit the L⇌R equilibrium in 2P-ERK2 in different ways. In particular, Vertex-11e and SCH772984 confer conformational selection for R and L states, respectively, while GDC-0994
and AMP-PNP maintain the equilibrium exchange observed in apo 2P-ERK2.
Distinct binding modes for ERK2 complexed with nucleotide
In order to examine possible conformational differences between R and L states, we determined an X-ray structure of 2P-ERK2 co-crystallized with Mg 2+ -AMP-PNP ( Fig. 2A , Table S2 , PDBID:6OPG). Two Mg 2+ ions occupy protein kinase metal positions Me1 and Me2 (19) , and bridge the nucleotide P -oxygen atoms with N152 and D165, placing P in proximity to the catalytic base, D147. This differs significantly from a published structure of 0P-ERK2 complexed with ATP ( Fig. 2B ) (20) . The structures show striking differences in the positioning of the ribose ring, where nucleotide dihedral angles between ribose and adenine (O4'-C1'-N9-C8 and C2'-C1'-N9-C4) each differ by 50 degrees. In the inactive complex, P coordinates with only one bound Mg 2+ (Me2) and overlaps the position of P in 2P-ERK2:AMP-PNP, placing the Poxygens more than 6 Å from D147. In contrast, the P -oxygens are 3.9 Å from D147 in the degrees between the two complexes (Table S3) , as well as by movement of the N-terminal Glyrich loop towards the C-terminal domain (Fig. 2 ). In addition, conserved Lys52, which is disordered in the 0P-ERK2:ATP complex, is well-ordered and coordinated with Glu69 and P and P oxygens in the 2P-ERK2:AMP-PNP complex (Fig. 2 , Table S3 ). Thus, nucleotide-bound active ERK2 revealed closer domain and ion pair interactions within the catalytic site. Overall, the comparison between these structures suggests that the conformational exchange induced by activation of ERK2 allows a transition within the active site, from a non-productive nucleotide binding interaction with 0P-ERK2 to a productive binding mode in 2P-ERK2. We propose that the shift to the R state in 2P-ERK2 enables formation of a catalytically competent nucleotide complex.
X-ray structures of ERK2 complexed with inhibitors
Next we determined X-ray structures of 2P-ERK2 complexed with high-affinity inhibitors. Dual phosphorylated ERK2 complexed with Vertex-11e (PDBID:6OPK) or GDC-0994 (PDBID:6OPH) underwent significant remodeling of the activation loop and L16 loop regions, mirroring conformational changes seen in the active apoenzyme (Figs. S1, S4). Both complexes were comparable to 2P-ERK2:AMP-PNP with respect to domain closure and the bidentate Lys52-Glu69 salt bridge (Fig. 3A ,B, Table S3 ). Thus, the active site residues in the Vertex-11e and GDC-0994 co-crystals were aligned similarly to those in the productive kinase-nucleotide complex.
SCH772984 is larger than Vertex-11e or GDC-0994, due to an extended piperazine-phenylpyrimidine motif (Fig. S2) . In 0P-ERK2, this tricyclic motif disrupts stacking interactions between Y34 in the Gly-rich loop and Y62 in helix C and forms new -stacking interactions between Y62 and the ligand (24) . We solved an X-ray structure of 2P-ERK2 complexed with a close analogue of SCH772984, SCH-CPD336, which contains a partially saturated pyridine ring in place of the piperazine and two decorations at the opposite end of the molecule (Fig S2, PDBID:6OPI). SCH-CPD336 binds 2P-ERK2 with high affinity (K d = 2.2 nM, measured by surface plasmon resonance, data not shown) and serves as a model for interactions between SCH772984 and the active kinase. As in the 0P-ERK2:SCH772984 complex, SCH-CPD336 disrupted Y34-Y62 stacking in 2P-ERK2, resulting in a monodentate Lys52-Glu69 interaction due to inhibitor-induced displacement of Lys52 (Fig. 3C , Table S3 ). The C-E dihedral angle in 2P-ERK2:SCH-CPD336 indicated an open conformation between N-and C-terminal domains, similar to that of 0P-ERK2:SCH772984, and closer to the apo-and nucleotide-bound forms of 0P-ERK2 than 2P-ERK2 (Table S3) . Thus, 2P-ERK2 complexed with the SCH772984 analogue reveals a more open conformation compared to complexes with Vertex-11e and GDC-0994.
We compared these structures against reported inhibitor complexes with 0P-ERK2 (17, 24) .
Nearly identical interactions were observed with both inactive and active forms of ERK2, with respect to inhibitor conformation and contacts with active site residues (Fig. 3, Fig. S4 ). Thus, unlike the nucleotide-bound complexes, structural differences between high affinity ligands bound to active vs inactive states of ERK2 were not detectable from X-ray data. Conceivably, the crystal forms may have masked differential binding modes through conformational trapping.
Alternatively, the complexes might differ in conformational mobility around similar average conformations. Therefore, we hypothesized that solution measurements might be needed to observe differences corresponding to L and R states observed by NMR.
HX-MS reveals differential inhibitor binding to the active site, coupled to the activation loop
HX-MS is a sensitive reporter of localized changes in structure and conformational mobility (25) .
We used HX-MS to examine effects of each inhibitor on deuterium uptake from solvent D 2 O, comparing active and inactive forms of ERK2 (Dataset S1). Inhibitor binding protected conserved regions in the active site pocket including the Gly-rich loop, helix C, the hinge region, and the DFG motif (Fig. S5, S6 ), all of which were readily explained by proximity to the binding site. Long range effects were also indicated by protection of the L16 helix (Fig. S5, S6 ). Deuterium uptake at the activation loop could not be compared directly between 0P and 2P kinase forms, due to differential proteolytic cleavage. However, structural changes could be monitored indirectly from the behavior of adjacent regions contacting the activation loop, including the P+1 substrate positioning loop and the N-terminal region of helix F (Fig. S7) .
The inhibitors altered deuterium uptake in two key regions that were instructive for understanding L and R conformations. The first was the DFG motif, which coordinates Mg 2+ in the catalytic site. Here, AMP-PNP binding protected peptide LKICDFGL from hydrogen exchange to a greater degree in active ERK2 compared to inactive enzyme (Fig. 4A) . The enhanced protection in 2P-ERK2 matched the X-ray evidence for a shift from nonproductive to productive nucleotide binding modes upon kinase activation, with greater steric protection from solvent due to closer interactions between P /Mg 2+ and DFG (cf. Fig. 2 ). GDC-0994 binding had comparable effects, also showing greater HX protection of the DFG region in active enzyme (Fig. 4B) . Strikingly, Vertex-11e binding resulted in a significantly higher degree of protection, strongly interfering with deuterium uptake in 2P-ERK2 (Fig. 4C) . Thus, the extent of HX protection of the DFG region was correlated with the degree of conformational selection for the R state in 2P-ERK2 complexed with AMP-PNP, GDC-0994 and Vertex-11e. By contrast, SCH772984, which is closer to the DFG motif due to its larger size, showed maximal HX protection in both 0P-and 2P-ERK2 (Fig. 4D) . Overall, the varying patterns of protection of the DFG motif provided evidence for differential binding interactions between 0P-ERK2 and 2P-ERK2 for ligands able to form the R state in 2P-ERK2, whereas protection by SCH772984 was consistent with a single binding interaction.
Deuterium uptake also reflected L and R states in the P+1 loop and F N-terminus. This region is closely linked to the activation loop, and neither it nor the activation loop directly contact ligand (cf. 
Inhibitor binding modulates ERK dephosphorylation
The HX results revealed that Vertex-11e and SCH772984 control conformational changes at the activation loop, suggesting that the activation loop is coupled to global exchange within the kinase core. Specifically, the results imply that the dually phosphorylated activation loop undergoes motions that track the L⇌R equilibrium. We considered the possibility that conformation-selective inhibitors alter the dynamics of the activation loop in a manner that affects regulatory mechanisms for ERK2. Previous studies have reported effects of Vertex-11e
and SCH772984 on the steady state phosphorylation of ERK1/2 in human cancer cells (17, 24, 26) . Often, SCH772984 treatment suppresses dual phosphorylation of ERK1/2, while Vertex-11e increases phosphorylation, without affecting the activity state of MKK1/2. Therefore, we investigated whether these inhibitors could affect dephosphorylation of 2P-ERK2 catalyzed by the MAP kinase phosphatase, MKP3/DUSP6. As demonstrated previously (27) and confirmed by MS/MS sequencing (data not shown), MKP3 dephosphorylates pY185 first to yield pT183-monophosphorylated (1P) ERK2, followed by removal of pT183 to yield 0P-ERK2.
Therefore, time courses were fit to apparent first order rate constants for stepwise dephosphorylation of 2P-to 1P-ERK2 (k 1 ) and 1P-to 0P-ERK2 (k 2 ). Vertex-11e binding decreased k 1 2.5-fold compared to apoenzyme, while SCH772984 binding increased k 1 3-fold (Fig. 6 , Table S4 ). Neither inhibitor significantly affected k 2 . GDC-0994 does not alter phosphorylation of cellular ERK1/2 (26), and neither it nor AMP-PNP affected MKP3-catalyzed dephosphorylation of 2P-ERK2 (Table S4) 
DISCUSSION
Our study demonstrates that tight-binding inhibitors of ERK2 exhibit conformational selection for distinct allosteric states that are involved in L⇌R interconversion. By combining solution measurements and X-ray crystallography to monitor conformational changes induced by these inhibitors, we show that L and R states correspond to small but significant movements within the active site, which are coupled to larger motions of the activation loop. Our findings reveal that the activation loop undergoes exchange in the apo state of dual phosphorylated ERK2 and that motions of the activation loop can be controlled allosterically by inhibitor binding. As a consequence, inhibitors that bind with conformational selection can control the accessibility of the pT183 and pY185 phosphorylation sites to MAP kinase phosphatase. Thus, we propose that the dynamics of the activation loop in 2P-ERK2 function to facilitate its recognition by regulatory proteins, such as MAP kinase phosphatases (Fig. 7) .
Our findings provide insights into the conformational differences between L and R states. The NMR measurements of global exchange behavior at Ile, Leu, and Val methyls throughout the kinase core predict that the L and R states involve residues throughout the N-and C-domains and catalytic pocket. But while X-ray structures of 0P-ERK2 and 2P-ERK2 apoenzymes showed large changes at the activation loop and the L16 loop (Fig. S1 ), structural differences within the active site were less apparent. Our new structure of active, phosphorylated ERK2 complexed with AMP-PNP helps clarify these differences by revealing a nucleotide binding mode distinct from that of inactive, unphosphorylated ERK2 complexed with ATP. Here, the position of the Gly-rich loop in 0P-ERK2 allows a nucleotide conformation that places the P -oxygen atoms >6
Å from the catalytic base. In the nucleotide complex with 2P-ERK2, closure of the Gly loop repositions the P -oxygen closer to the catalytic base and also allows coordination of an additional Mg 2+ ion, which is needed for full activity (28) . Compared to 0P-ERK2:ATP, the 2P-ERK2:AMP-PNP complex also shows displacement of helix C relative to helix E, reflecting Ndomain rotation and closure (23) . These differences provide a structural interpretation of corresponding HX-MS measurements which reflect distinct binding interactions between AMP-PNP and the conserved DFG motif. It is significant that none of these changes alter the orientation of the DFG motif, which remains in the DFG-in state. Instead, the allosteric switch from L to R following ERK2 phosphorylation involves small differences in conformation of enzyme and nucleotide, leading to a shift from a nonproductive to a productive nucleotide binding mode. In this way, motions that allow L R conversion can be associated with a shift to a catalytically competent state. Outside the catalytic site, ERK2 activation induced larger conformational changes. Vertex-11e
or GDC-0994 binding to 2P-ERK2 allowed remodeling of the activation loop and L16 region, similar to apoenzyme. In contrast, SCH-CPD336 bound to 2P-ERK2 showed disorder in the activation loop and L16 regions, likely due to the disruption of Gly-rich loop and C interactions by the piperazine-phenyl-pyrimidine moiety. These structural changes agreed well with differences in hydrogen exchange protection in the P+1 and F N-terminal region, which reports conformational change at the activation loop. Importantly, the enhanced degree of HX protection by Vertex-11e compared to AMP-PNP or GDC-0994 matched that expected for its shift of the L⇌R equilibrium further towards the R state. These findings suggest coupling between inhibitor occupancy of the active site and the distally-located activation loop.
Taken together, the solution measurements and crystal structures are consistent with a model in which dynamics of the activation loop are associated with the equilibrium between L and R in 2P-ERK2. This model differs from structural analyses suggesting an activation loop conformation in the active kinase which is stabilized by an extensive salt bridge network between pT183, pY185 and five Arg sidechains (R68, R146, R170, R189, R192) (5).
Conceivably, favorable enthalpic contributions from these salt bridges could be counteracted by a loss in entropy due to residue immobilization (29) . This may explain the small difference in free energy (~0.8 kcal/mol) favoring R over L, measured by NMR (11) . The low energetic barrier allows Vertex-11e to trap the active conformation of the activation loop, and SCH772984 to disrupt it. 
MATERIALS AND METHODS
Vertex-11e, SCH772984, and GDC-0994 were obtained from Selleck Chemicals and adenylylimidodiphosphate (AMP-PNP) was from Sigma-Aldrich. SCH-CPD336 was synthesized inhouse, following methods described in US Patent WO2007070298A1, example 336. 0P-ERK2
and 2P-ERK2 [methyl-1 H, 13 C]-ILV labelled at ILV for NMR or unlabelled for HX-MS were prepared as described (11, 14, 15) . Detailed methods for measurements by NMR, HX-MS and X-ray crystallography followed previously described protocols. Views of the full-length kinases are shown in Fig. S4 . MKP3 was incubated with 2P-ERK2 for indicated times, and mass spectrometry was used to quantify 2P, 1P (monophosphorylated-pT183) and 0P forms, in (A) apoenzyme, (B) Vertex-11e bound, and (C) SCH772984-bound ERK2. First order rate constants and errors for stepwise dephosphorylation events are presented in Table S4 . Vertex-11e binding decreases the rate constant for the conversion of 2P-ERK2 1P-ERK2 by two-fold, while SCH772984 increases it by three-fold. 
